ICON Public Limited (NASDAQ:ICLR) Receives Average Rating of “Buy” from Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have received a consensus rating of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $321.64.

Several research analysts have recently weighed in on the company. Robert W. Baird upped their price objective on ICON Public from $362.00 to $363.00 and gave the stock an “outperform” rating in a research report on Friday. TD Cowen upped their price objective on ICON Public from $343.00 to $349.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial upped their price objective on ICON Public from $357.00 to $367.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Barclays upped their price objective on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Mizuho reiterated a “buy” rating and set a $346.00 target price on shares of ICON Public in a report on Thursday, April 4th.

ICON Public Stock Up 2.7 %

NASDAQ:ICLR opened at $308.31 on Friday. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The stock has a market cap of $25.43 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 1.46 and a beta of 1.15. The stock has a 50-day moving average price of $318.89 and a two-hundred day moving average price of $282.81.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.13. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.08 billion. ICON Public had a return on equity of 11.84% and a net margin of 8.30%. As a group, equities analysts expect that ICON Public will post 14.4 earnings per share for the current year.

Institutional Trading of ICON Public

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bruce G. Allen Investments LLC bought a new position in shares of ICON Public during the fourth quarter worth approximately $25,000. Riverview Trust Co bought a new position in shares of ICON Public during the first quarter worth approximately $31,000. Livelsberger Financial Advisory bought a new position in shares of ICON Public during the fourth quarter worth approximately $29,000. Pinnacle Bancorp Inc. increased its stake in shares of ICON Public by 110.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after purchasing an additional 55 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of ICON Public during the fourth quarter worth approximately $37,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.